RxDoctor Payments Data

David Mudd, MD

Internal Medicine · Brockton, MANPI 1750376794

Payments from drug & device makers

$5,667in general payments, 2019–2025

Across 303 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$803
  • Novo Nordisk$667
  • Amgen$426
  • E.r. Squibb & Sons, L.L.C.$389
  • Lilly USA, LLC$352
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,667 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$196,288
Medicare patients
359
Services billed
3,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$112,330
JardianceEmpagliflozin54$71,548
OzempicSemaglutide46$46,730
OxycontinOxycodone Hcl36$41,442
XareltoRivaroxaban47$39,489
JanuviaSitagliptin Phosphate32$33,192
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$22,947
Tresiba Flextouch U-200Insulin Degludec18$22,541
RybelsusSemaglutide13$17,376
Breo ElliptaFluticasone/Vilanterol21$16,447
Fiasp FlextouchInsulin Aspart (Niacinamide)11$14,981
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$9,090
Atorvastatin Calcium497$6,947
SymbicortBudesonide/Formoterol Fumarate19$4,966
Gabapentin235$4,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,021$112,330100 claims
Boehringer IngelheimJardiance$164$71,54854 claims
Novo NordiskOzempic, Rybelsus$667$64,10759 claims
Johnson & JohnsonXarelto$97$39,48947 claims
MerckJanuvia$121$33,19232 claims
GSKBreo Ellipta$108$16,44721 claims
AstraZenecaSymbicort$291$4,96619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →